Talking Life Sciences

Covington & Burling
  • 0.0 (0)
  • LIFE SCIENCES

Covington's Talking Life Sciences Podcast offers snapshot insights into topical EMEA wide issues and trends affecting the Life Sciences sector. Subscribe to our EU Life Sciences blog to receive notifications on new episodes.

  1. 24/10/2024

    Episode 18 - Regulatory and Policy Developments from South Africa – SAHPRA's Proposed Black Economic Empowerment (BEE) Policy

    In this episode of Covington's Life Sciences Podcast, Mosa Mkhize and Deon Govender discuss Regulatory and policy developments from South Africa: SAHPRA's proposed Black Economic Empowerment (BEE) policy and its potential impact on license holders for medicines and medical devices

    14 min

  2. 15/10/2024

    Episode 17 - Developments in the African Medicines Agency and Regulatory Convergence

    In this episode of Covington's Life Sciences Podcast, Mosa Mkhize and Grant Castle discuss developments in the African Medicines Agency and regulatory convergence.

    17 min

  3. 07/10/2024

    Episode 16 - WHO Prequalification Procedures in Africa

    In this episode of Covington's Life Sciences Podcast, Mosa Mkhize and Roderick Dirkzwager discuss WHO prequalification procedures in Africa.

    18 min

  4. 13/06/2024

    Episode 15 - Green Claims – Recent Developments in EU Regulation and Enforcement

    In this episode of Covington's Life Sciences Podcast, Seán Finan discuss some important recent developments in the regulation of sustainability and green claims and labelling schemes, and the ever-increasing enforcement risk that comes with greenwashing.

    20 min

  5. 10/05/2024

    Episode 14 - EU Pharma Law Review – Focus on Incentives

    In this episode of Covington's Life Sciences Podcast, Marie Doyle-Rossi, Anna Wawrzyniak, and Valeria Sturla discuss the position adopted by the European Parliament on 10 April 2024 on the Commission proposal to reform the core EU pharmaceutical legislation. Parliament's position comes less than a year since the Commission published its proposal, and constitutes a significant step in the legislative process. Although many of the Parliament's amendments to the Commission proposal can be seen as improvements by the innovative industry, many challenges and some unresolved questions remain, especially in relation to the incentive regime. During this audiocast, we therefore discuss improvements, challenges and unresolved questions of the EU Pharma law review, with a particular focus on incentives.

    15 min

  6. 01/04/2024

    Episode 13 – Defining innovation markets – applying the new market definition notice to Life Science deals

    Tune into this episode of Covington's Life Sciences Podcast, where Sibel Yilmaz, Majken Lagerbielke, and Leire Garagorri Eguidazu discuss the new market definition notice published by DG COMP, specifically the latest on the new guidance concerning pharmaceutical innovation markets and possible implications for analysing M&A and licensing deals.

    13 min

  7. 26/03/2024

    Episode 12 - Life Sciences Transactions – Outlook and Trends for 2024

    Tune into this episode of Covington's Life Sciences Podcast, where Winsome Cheung and George Jenkins discuss the key trends in Life Sciences Transactions for 2024. The speakers discuss the outlook for deal-making in Life Sciences and predictions for deal trends, including in relation to nuclear medicine, GLP-1, antibody-drug conjugates and other modalities. The speakers also discuss some of the key legal considerations that are coming into increasing focus for Life Sciences Transactions, such as competition/antitrust considerations and the Inflation Reduction Act. This is the first Life Sciences Transactions audiocast for 2024, and we plan to release further audiocasts over the course of this year that dive deeper into some of the above topics.

    16 min

  8. 12/12/2023

    Episode 11 - Major Changes to the UK's Price Control Schemes for Branded Medicines – VPAG and the New Statutory Scheme – What You Need to Know

    Recently announced changes to the Voluntary Scheme (VPAG) and Statutory Scheme change the paradigm for the pricing of branded medicines in the UK. Innovative pharmaceutical companies doing business in the UK must decide which scheme to join for 2024 – a decision that may significantly affect margins. Tune into this episode of Covington's Life Sciences Podcast, to hear the latest on these changes from our experts, Grant Castle, Raj Gathani and Daniel Spivey.

    18 min
See All (18)

About

Covington's Talking Life Sciences Podcast offers snapshot insights into topical EMEA wide issues and trends affecting the Life Sciences sector. Subscribe to our EU Life Sciences blog to receive notifications on new episodes.

Information

More From Covington & Burling